Get Investing Superpowers With StockStory
StockStory Edge is an AI-enabled, human-guided service specifically designed to help individual investors such as yourself beat the market.
Trusted by 200,000+ investors
StockStory Beats The Market
StockStory’s High Quality stocks generated a market-beating return of 175% from September 30, 2019 to September 30, 2024 vs an 94% return for the market (S&P 500).
*Read the report for detailed and technical information about our investment framework and performance methodology
StockStory Edge achieves this outperformance by utilizing AI and quantitative analysis to identify high-quality stocks and opportunities overlooked by the market.
How StockStory Works?Stock of the Day
StockStory empowers you to invest in high-quality companies at attractive prices. These are excellent businesses with defensible moats that operate in growing markets.
Trusted By Many
Over 200,000 Investors Trust StockStory
Access monthly stock picks by our market-beating team, find opportunities in stocks flying under Wall Street’s radar, and get actionable insights to make the right decisions whether the market is going up or down.
Their quality of research never ceases to impress me. StockStory quickly became my favorite way to get news on my portfolio and their picks are an awesome way to find new investments.
I don't have time to do research and stay on top of market news. StockStory really helps me by providing guidance I can trust.
Latest Stories
2 Reasons to Sell PRVA and 1 Stock to Buy Instead
Even during a down period for the markets, Privia Health has gone against the grain, climbing to $22.91. Its shares have yielded a 29.3% return over the last six months, beating the S&P 500 by 30.9%. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical (NASDAQ:COLL) and the rest of the branded pharmaceuticals stocks fared in Q4.
Waste Management (WM): Buy, Sell, or Hold Post Q4 Earnings?
While the broader market has struggled with the S&P 500 down 1.7% since October 2024, Waste Management has surged ahead as its stock price has climbed by 13% to $234.23 per share. This performance may have investors wondering how to approach the situation.
Investing Is Changing, Can You Keep Up?
AI-enabled research is revolutionizing investing, but so far only large institutions and professional funds have benefitted from it.
That doesn’t seem fair to us. We’ve seen over the years how many small, patient investors have made life-changing money, and we don’t want to leave them behind.
We started StockStory to help you beat the market and give you the same AI-driven edge as hedge funds.
For the first time, our proprietary data sets, cutting-edge AI, and market-beating research are designed specifically for you, the individual investor.
Trusted by 200,000+ investors
FeaturesStockStory Edge: What You Get
Monthly Stock Picks
Our market-beating team hand-picks one outstanding stock every month. These are rare opportunities we trust so much that we back them with our own money.
Find High Quality Stocks
Actionable research reports on hundreds of stocks, updated daily. We help you find high-quality businesses that are set to outperform the market over the long-term.
Beat Others With The Fastest Earnings Updates
Our earnings analysis is in your inbox within minutes from the data being released. We are the fastest in the market, giving you a big advantage over other investors.
Discover Hidden Gems
All great stocks started as small stocks. We find them first. That’s the power of AI.
Understand Why Stocks Move
Every time a stock moves more than 5% on an identifiable catalyst—or 2.5% for mega caps—we provide you with a timely explanation, sent straight to your inbox.
Partners We Work With
Trusted by 200,000+ investors